Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)
23 Mar 2018
Mon, Mar 12 2018
* CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE
* CORBUS PHARMACEUTICALS RECEIVES $25 MILLION DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION TO SUPPORT PHASE 2B CLINICAL STUDY OF LENABASUM Source text for Eikon: Further company coverage:
BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint
* CORBUS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2B CYSTIC FIBROSIS STUDY DESIGN WITH PULMONARY EXACERBATIONS AS SOLE PRIMARY ENDPOINT
Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.
Jan 29 Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.
* CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2EciBBu) Further company coverage:
BRIEF-Corbus Pharma Initiates Phase 2 Study Of Anabasum For Treatment Of Systemic Lupus Erythematosus
* CORBUS PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2 STUDY OF ANABASUM FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:
* Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements
* Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study
* Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock
- Corbus Pharmaceuticals (CRBP) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
- Which Marijuana ETF Is Best For You?
- Marijuana Stocks That Could Outpace The Market In 2018
- Corbus Buying Opportunity As Shares Fall With Biotech Sector On $25M Cystic Fibrosis Grant
- Corbus Is A Buy, But Not For Cystic Fibrosis
- Corbus Pharmaceuticals (CRBP) Corporate Presentation - Slideshow